E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Residual or recurrent Cervical Intraepithelial Neoplasia (CIN) |
Recidief of residue CIN (cervicale intraepitheliale neoplasie) |
|
E.1.1.1 | Medical condition in easily understood language |
Precancerous lesions of the cervix despite previous operative treatment |
Voorstadium van baarmoederhalskanker ondanks eerdere behandeling |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of the efficacy of imiquimod 5% cream compared to treatment with Large Loop excision of the transformation zone (LLETZ) for recurrent/residual CIN. |
Evaluatie van de effectiviteit van Imiquimod 5% creme vergeleken met de LLETZ (Large Loop Excision of transformation zone) voor recidief of residue CIN afwijkingen |
|
E.2.2 | Secondary objectives of the trial |
Evaluation of the effect of treatments on HPV DNA presence in CIN lesions Evaluations of tolerability of imiquimod in CIN lesions Evaluation of quality of life Establishment of long term recurrence rate of CIN lesions |
Effect van behandeling op HPV DNA aanwezigheid in CIN leasies Verdraagbaarheid van Imiquimod bij CIN laesies Quality of life Lange termijn behandelingsresultaten |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Histologically proven CIN2 or CIN 3, without invasion after previous surgical treatment at least 6 months before diagnosis - Histologically proven persistent CIN 1 after previous surigcal treament at least 6 months before diagnosis. Persistent CIN 1 is defined as CIN 1 at least persistent for 6 months and proven with histology - The patient is willing to use a medically acceptable method of contraception throughout the study - Women older than 18 years of age |
- Histologisch bewezen CIN 2 of CIN 3 zonder invasie na eerdere chirurgische behandeling minstens 6 maanden voor de diagnose - Histologisch bewezen persisterende CIN1 na eerdere chirurgische behandeling ten minste 6 maanden voor de diagnose. Persisterende CIN 1 is gedefineerd als CIN voor ten minste 6 maanden persisterend en bewezen met histologie. - De patiente gebruikt een acceptabele methode van anticonceptie gedurende de studie - vrouwen ouder dan 18 jaar |
|
E.4 | Principal exclusion criteria |
- Pregnancy or lactation - (Micro-)invasive carcinoma - Past history of cervical cancer - Hypersensitivity of any components of the formulation - History of psoriasis or other inflammatory dermatosis of the vulva - Immunodeficiency or treatment with immunosuppressive medication - Insufficient understanding of the Dutch or English language
|
- zwangerschap of lactatie - (micro) invasief carcinoom - voorgeschiedenis van cervixcarcinoom - Overgevoeligheid voor de bestandsdelen van de medicatie - voorgeschiedenis van psoriasis of andere inflammatoire dermatosen van de vulva - Immuuncompressie of behandeling met immunocompressiva - onvoldoende begrip van nederlandse of engelse taal |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Reduction from CIN 2-3 or persistent CIN 1 to normal cytology 6 months after start treatment. |
- afname van CIN2-3 of persisterende CIN 1 tot normale cytologie 6 maanden na de behandeling |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 months after start treatment |
6 maanden na start behandeling |
|
E.5.2 | Secondary end point(s) |
o Presence or absence of HPV DNA in CIN lesions at 0 and 26 weeks. o Reduction from CIN to no dysplasia 10 weeks after the treatment with imiquimod. o Improvement in quality of life o Side effects of imiquimod o Durability of the clinical response at 12 and 24 months o Long term recurrence defined by follow up in the screening program for cervical cancer in The Netherlands
|
- aanwezigheid of afwezigheid van HPV DNA in CIN laesies op week 0 en week 26 - reductie van CIN naar geen dysplasie 10 weken na de behandeling met imiquimod - verbeterig in kwaliteit van leven - bijwerkingen van imiquimod - duur van de klinische respons bij maand 12 en 24 - lange termijn uitkomsten gedefineerd als eerste uitstrijkje bij follow up in het Nederlandse screening programma ter preventie van cervicarcinoom |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- 10 weeks after treatment with imiquimod - at inclusion, 6 and 12 months after treatment - during the treatment with imiquimod - 12 and 24 months after start treatment - first cervical smear according to dutch screening program |
- 10 weken na de behandeling met imiquimod - bij inclusie, 6 en 12 maanden na behandeling - gedurende de behandeling met Imiquimod - 12 en 24 maanden na start behandeling - eerste uitstrijkje volgens het Nederlandse screening programma |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Large Loop Excision of the transformation Zone (LLETZ) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Trial will end when 276 patients are included If any unexpected severe side effects occur, the study will be prematurely terminated after advise of the DMSB. A Serious Adverse Event is any untoward medical occurrence or effect that at any dose - results in death - is life threatening - requires hospitalisation or prolongation of existing hospitalisation - results in persistent or significant disability or incapacity - is a new event of the trial likely to affect the safety of the subjects |
Trial zal eindigen na inclusie van 276 patienten. Bij optreden onverwachte ernstige bijwerkingen, zal de studie beeindigd worden na advies van de DMSB. Een ernstige bijwerking is een ongunstige medische gebeurtenis dat in elke dosering: leidt tot overlijden -levensbedreigend is - ziekenhuis opname vereist of verlenging van bestaande opname - resulteert in peristerende of significante handicap - een nieuw evenement van de trial die waarschijnlijk de veiligeid van de deelnemers beinvloedt |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |